Возможности прогнозирования манифестации HELLP‑синдрома

Введение. Несмотря на использование современных принципов лечения тяжелой преэклампсии, показатели летальности для матери и новорожденного при развитии такого жизнеугрожающего осложнения, как HELLP-синдром, остаются высокими. Внедрение в повседневную врачебную практику точных моделей ранней диагностики и прогнозирования вероятности манифестации и тяжести течения HELLP-синдрома позволит повысить безопасность родоразрешения беременных с тяжелой преэклампсией.

Цель исследования — определить современное состояние вопроса и систематизировать текущие данные о методах прогнозирования вероятности манифестации HELLP-синдрома.

Материалы и методы. Проведен качественный анализ клинических испытаний и обзоров, посвященных прогнозированию развития HELLP-синдрома, с использованием базы данных PubMed и поисковой системы Google Scholar. Поиск выполнялся на русском и английском языках по ключевым словам «предикторы», или «предикция», или «прогнозирование», и «HELLP-синдром». Дата последнего поискового запроса: 22 марта 2024 г.

Результаты. Проанализированы анамнестические данные и исходные характеристики пациенток с HELLP-синдромом.

Обсуждение. В аналитический обзор вошли публикации, посвященные изучению влияния предикторных возможностей потенциальных биохимических маркеров, клинико-анамнестических признаков и данных инструментального обследования на вероятность развития HELLP-синдрома.

Выводы. Адекватное прогнозирование манифестации HELLP-синдрома возможно на основе комплексного анализа всех выявленных факторов, позволяющего определить эффективные прогностические модели в целях улучшения исходов для матери и плода у беременных с тяжелой преэклампсией.

1. Adorno M, Maher-Griffiths C, Grush Abadie HR. HELLP syndrome. Critical Care Nursing Clinics of North America. 2022;34(3):277–288. DOI: https://doi.org/10.1016/j.cnc.2022.04.009.

2. Pritchard JA, Weisman R Jr, Ratnoff OD, Vosburgh GJ. Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. The New England Journal of Medicine. 1954;250(3):89–98. DOI: https://doi.org/10.1056/NEJM195401212500301.

3. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: A severe consequence of hypertension in pregnancy. American Journal of Obstetrics & Gynecology. 1982;142(2):159–167. DOI: https://doi.org/10.1016/s0002–9378(16)32330-4.

4. Alese MO, Moodley J, Naicker T. Preeclampsia and HELLP syndrome, the role of the liver. The Journal of Maternal-Fetal & Neonatal Medicine. 2021;34(1):117–123. DOI: https://doi.org/10.1080/14767058.2019.1572737.

5. Aloizos S, Seretis C, Liakos N, Aravosita P, Mystakelli C, Kanna E, et al. HELLP syndrome: Understanding and management of a pregnancy-specific disease. Journal of Obstetrics and Gynaecology. 2013;33(4):331–337. DOI: https://doi.org/10.3109/01443615.2013.775231.

6. Lam MTC, Dierking E. Intensive Care Unit issues in eclampsia and HELLP syndrome. International Journal of Critical Illness and Injury Science. 2017;7(3):136–141. DOI: https://doi.org/10.4103/IJCIIS.IJCIIS_33_17.

7. Tsoy VYu, Olimova FZ, Uzakova UD, Dodkhoyeva MF, Abdullayeva RA, Mukhamadieva SM. Risk factors for perinatal loss in women with HELLP syndrome. Doctor.Ru. 2019;4(159):23–27. (In Russ.). DOI: https://doi.org/10.31550/1727-2378-2019-159-4-23-27.

8. Van Lieshout LCEW, Koek GH, Spaanderman MA, van Runnard Heimel PJ. Placenta derived factors involved in the pathogenesis of the liver in the syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP): A review. Pregnancy Hypertension.2019;18:42–48. DOI: https://doi.org/10.1016/j.preghy.2019.08.004.

9. Lisonkova S, Razaz N, Sabr Y, Muraca GM, Boutin A, Mayer C, et al. Maternal risk factors and adverse birth outcomes associated with HELLP syndrome: A population-based study. BJOG. 2020;127(10):1189–1198. DOI: https://doi.org/10.1111/1471-0528.16225.

10. Petca A, Miron BC, Pacu I, Dumitrașcu MC, Mehedințu C, Șandru F, et al. HELLP syndrome — Holistic insight into pathophysiology. Medicina. 2022;58(2):326. DOI: https://doi.org/10.3390/medicina58020326.

11. Tabacco S, Ambrosii S, Polsinelli V, Fantasia I, D’Alfonso A, Ludovisi M, et al. Pre-eclampsia: From etiology and molecular mechanisms to clinical tools — A review of the literature. Current Issues in Molecular Biology. 2023;45(8):6202–6215. DOI: https://doi.org/10.3390/cimb45080391.

12. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (eds.). Cochranehandbook for systematic reviews of interventions. 2nd ed. Chichester: John Wiley & Sons, 2019. XXIII, 694 p. Available from: https://goo.su/ATalku [accessed 15 March 2024].

13. Oliveira N, Poon LC, Nicolaides KH, Baschat AA. First trimester prediction of HELLP syndrome. Prenatal Diagnosis. 2016;36(1):29–33. DOI: https://doi.org/10.1002/pd.4694.

14. Dongarwar D, Adindu EK, Mizu R, Salihu HM. Racial/ethnic disparities in preeclampsia, eclampsia, and HELLP syndrome hospitalizations rates in the United States. International Journal of Translational Medical Research and Public Health. 2022;6(1): e401. DOI: https://doi.org/10.21106/ijtmrph.401.

15. Chornock R, Iqbal SN, Kawakita T. Racial disparity in postpartum readmission due to hypertension among women with pregnancy-associated hypertension. American Journal of Perinatology. 2021;38(12):1297–1302. DOI: https://doi.org/10.1055/s-0040-1712530.

16. Malmström O, Morken NH. HELLP syndrome, risk factors in first and second pregnancy: A population-based cohort study. Acta Obstetricia et Gynecologica Scandinavica. 2018;97(6):709–716. DOI: https://doi.org/10.1111/aogs.13322.

17. Várkonyi T, Nagy B, Füle T, Tarca AL, Karászi K, Schönléber J, et al. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta. 2011;32 (Suppl 1): S21–S29. DOI: https://doi.org/10.1016/j.placenta.2010.04.014.

18. Gardikioti A, Venou TM, Gavriilaki E, Vetsiou E, Mavrikou I, Dinas K, et al. Molecular advances in preeclampsia and HELLP syndrome. International Journal of Molecular Sciences. 2022;23(7):3851. DOI: https://doi.org/10.3390/ijms23073851.

19. Haram K, Mortensen JH, Nagy B. Genetic aspects of preeclampsia and the HELLP syndrome. Journal of Pregnancy. 2014;2014:910751. DOI: https://doi.org/10.1155/2014/910751.

20. Khalid F, Mahendraker N, Tonismae T. HELLP syndrome. In: StatPearls. Treasure Island: StatPearls Publishing; 2024. PMID: 32809450.

21. Stojanovska V, Zenclussen AC. Innate and adaptive immune responses in HELLP syndrome. Frontiers in Immunology. 2020;11:667. DOI: https://doi.org/10.3389/fimmu.2020.00667.

22. Hromadnikova I, Kotlabova K, Krofta L. First-trimester screening for HELLP syndrome-prediction model based on microRNA biomarkers and maternal clinical characteristics. International Journal of Molecular Sciences. 2023;24(6):5177. DOI: https://doi.org/10.3390/ijms24065177.

23. Rezende KBC, Cunha AJLA, Amim J Jr, Oliveira WM, Leão MEB, Menezes MOA, et al. Performance of fetal medicine foundation software for pre-eclampsia prediction upon marker customization: Cross-sectional study. Journal of Medical Internet Research. 2019;21(11): e14738. DOI: https://doi.org/10.2196/14738.

24. Jiménez KM, Morel A, Parada-Niño L, Alejandra González-Rodriguez M, Flórez S, Bolívar-Salazar D, et al. Identifying new potential genetic biomarkers for HELLP syndrome using massive parallel sequencing. Pregnancy Hypertension.2020;22:181–190. DOI: https://doi.org/10.1016/j.preghy.2020.09.003.

25. Berryman K, Buhimschi CS, Zhao G, Axe M, Locke M, Buhimschi IA. Proteasome levels and activity in pregnancies complicated by severe preeclampsia and hemolysis, elevated liver enzymes, and thrombocytopenia (HELLP) syndrome. Hypertension. 2019;73(6):1308–1318. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.118.12437.

26. Cadoret F, Guerby P, Cavaignac-Vitalis M, Vayssiere C, Parant O, Vidal F. Expectant management in HELLP syndrome: Predictive factors of disease evolution. The Journal of Maternal-Fetal & Neonatal Medicine. 2021;34(24):4029–4034. DOI: https://doi.org/10.1080/14767058.2019.1702956.

27. Polat I, Gedikbasi A, Kiyak H, Gulac B, Atis A, Goynumer G, et al. Double notches: Association of uterine artery notch forms with pregnancy outcome and severity of preeclampsia. Hypertension in Pregnancy. 2015;34(1):90–101. DOI: https://doi.org/10.3109/10641955.2014.982330.

28. Chen MF, Chen XN, Zhang ZW, Chen DQ. Clinical comparative analysis of early-onset preeclampsia combined with HELLP syndrome. Sichuan Da XueXue Bao Yi Xue Ban. 2022;53(6):1033–1038. (In Chin.). DOI: https://doi.org/10.12182/20221160508.

29. Melinte-Popescu M, Vasilache IA, Socolov D, Melinte-Popescu AS. Prediction of HELLP syndrome severity using machine learning algorithms — Results from a retrospective study. Diagnostics. 2023;13(2):287. DOI: https://doi.org/10.3390/diagnostics13020287.

30. Huang H, Liu B, Gao X, Wang Y. Clinical classification, pregnancy outcomes and risk factors analysis of severe preeclampsia complicated with HELLP syndrome. Frontiers in Surgery. 2022:9:859180. DOI: https://doi.org/10.3389/fsurg.2022.859180.

31. Li Z, Dai Y, Yun L, Guo W. A prediction model for the progression from gestational hypertension to pre-eclampsia complicated with HELLP syndrome. International Journal of Gynecology & Obstetrics. 2023;165(3):1002–1012. DOI: https://doi.org/10.1002/ijgo.15274.

32. Guida JP, Cralcev C, Costa Santos J, Marangoni-Junior M, Sanchez MP, Laura Costa M. Validation of the fullPIERS model for prediction of adverse outcomes in preeclampsia at a referral center. Pregnancy Hypertension. 2021;23:112–115. DOI: https://doi.org/10.1016/j.preghy.2020.11.013.

33. Uckan K, Sahin HG. Serum amyloid A, procalcitonin, highly sensitive C reactive protein and tumor necrosis factor alpha levels and acute inflammatory response in patients with hemolysis, elevated liver enzymes, low platelet count (HELLP) and eclampsia. Journal of Obstetrics and Gynaecology Research. 2018;44(3):440–447. DOI: https://doi.org/10.1111/jog.13532.

34. Dal Y, Karagün Ş, Akkuş F, Akay K, Coşkun A. Are the serum delta neutrophil index and systemic inflammatory index useful as predictive parameters for preeclampsia and HELLP syndrome? Czech Gynaecology. 2023;88(6):412–419. DOI: https://doi.org/10.48095/cccg2023412.

35. Andreeva MD, Balayan IS, Karakhalis LYu. Early prognosis of preeclampsia: The reality of today. Obstetrics and Gynecology: News, Opinions, Training. 2023;11(1):19–27. (In Russ.). DOI: https://doi.org/10.33029/2303-9698-2023-11-1-19-27.

36. Agrawal N, Yadav P, Bishnoi S, Fayyaz S. Can high first trimester NLR and PLR is early predictor for preeclampsia?: An experience of single tertiary care center. Archives of Reproductive Medicine and Sexual Health. 2018;1:3–7. DOI: https://doi.org/10.22259/2639-1791.0102002.

37. Gezer C, Ekin A, Ertas IE, Ozeren M, Solmaz U, Mat E, et al. High first-trimester neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are indicators for early diagnosis of preeclampsia. Ginekologia Polska. 2016;87(6):431–435. DOI: https://doi.org/10.5603/GP.2016.0021.

38. Sisti G, Faraci A, Silva J, Upadhyay R. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and complete blood count components in the first trimester do not predict HELLP syndrome. Medicina. 2019;55(6):219. DOI: https://doi.org/10.3390/medicina55060219.

39. Kang SY, Wang Y, Zhou LP, Zhang H. New indicators in evaluation of hemolysis, elevated liver enzymes, and low platelet syndrome: A case-control study. World Journal of Clinical Cases. 2021;9(6):1259–1270. DOI: https://doi.org/10.12998/wjcc.v9.i6.1259.

40. Gedik E, Yücel N, Sahin T, Koca E, Colak YZ, Togal T. Hemolysis, elevated liver enzymes, and low platelet syndrome: Outcomes for patients admitted to intensive care at a tertiary referral hospital. Hypertension in Pregnancy. 2017;36(1):21–29. DOI: https://doi.org/10.1080/10641955.2016.1218505.

41. Mei F, Falchi N, Taramaschi D, Egidi MF, Bottone P, Bertolotto A, et al. LDH/AST ratio: A future resource for thrombotic microangiopathies differential diagnosis in pregnancy. Obstetrics & Gynecology International Journal. 2020;11(1):44‒48. Available from: https://clck.ru/3AmfaZ [accessed 15 March 2024].

42. Keiser SD, Boyd KW, Rehberg JF, Elkins S, Owens MY, Sunesara I, et al. A high LDH to AST ratio helps to differentiate pregnancy-associated thrombotic thrombocytopenic purpura (TTP) from HELLP syndrome. The Journal of Maternal-Fetal & Neonatal Medicine. 2012;25(7):1059–1063. DOI: https://doi.org/10.3109/14767058.2011.619603.

43. Ünal HB, Dal Y, Karagün Ş, Coşkun AJ. The role of haptoglobin in the diagnosis of preeclampsia and HELLP syndrome and in predicting neonatal outcomes. Journal of Obstetrics and Gynaecology Research. 2023;49(10):2410–2416. DOI: https://doi.org/10.1111/jog.15746.

44. Tolunay HE, Kahraman NC, Varli EN, Reis YA, Celen S, Caglar AT. Can first-trimester AST to platelet ratio index scores predict HELLP syndrome? Journal of the College of Physicians and Surgeons Pakistan. 2021;31(2):188–192. DOI: https://doi.org/10.29271/jcpsp.2021.02.188.

45. Şaşmaz Mİ, Ayvaz MA, Dülger AC, Kuday Kaykısız EK, Güven R. Aspartate-aminotransferase to platelet ratio index score for predicting HELLP syndrome. The American Journal of Emergency Medicine. 2020;38(3):459–462. DOI: https://doi.org/10.1016/j.ajem.2019.02.014.

46. Teirilä L, Heikkinen-Eloranta J, Kotimaa J, Meri S, Lokki AI. Regulation of the complement system and immunological tolerance in pregnancy. Seminars in Immunology. 2019;45:101337. DOI: https://doi.org/10.1016/j.smim.2019.101337.

47. Lokki AI, Heikkinen-Eloranta J, Jarva H, Saisto T, Lokki ML, Laivuori H, et al. Complement activation and regulation in preeclamptic placenta. Frontiers in Immunology.2014;5:312. DOI: https://doi.org/10.3389/fimmu.2014.00312.

48. Pierik E, Prins JR, van Goor H, Dekker GA, Daha MR, Seelen MAJ, et al. Dysregulation of complement activation and placental dysfunction: A potential target to treat preeclampsia? Frontiers in Immunology. 2020;10:3098. DOI: https://doi.org/10.3389/fimmu.2019.03098.

49. Denny KJ, Woodruff TM, Taylor SM, Callaway LK. Complement in pregnancy: A delicate balance. American Journal of Reproductive Immunology. 2013;69(1):3–11. DOI: https://doi.org/10.1111/aji.12000.

50. He YD, Xu BN, Song D, Wang YQ, Yu F, Chen Q, et al. Normal range of complement components during pregnancy: A prospective study. American Journal of Reproductive Immunology. 2020;83(2):e13202. DOI: https://doi.org/10.1111/aji.13202.

51. Bazzan M, Todros T, Tedeschi S, Ardissino G, Cardaropoli S, Stella S, et al. Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome. Thrombosis Research. 2020;196:167–174. DOI: https://doi.org/10.1016/j.thromres.2020.08.038.

52. Banadakoppa M, Balakrishnan M, Yallampalli C. Upregulation and release of soluble fms-like tyrosine kinase receptor 1 mediated by complement activation in human syncytiotrophoblast cells. American Journal of Reproductive Immunology. 2018;80(5): e13033. DOI: https://doi.org/10.1111/aji.13033.

53. Yonekura Collier AR, Zsengeller Z, Pernicone E, Salahuddin S, Khankin EV, Karumanchi SA. Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia. Hypertension in Pregnancy. 2019;38(3):193–199. DOI: https://doi.org/10.1080/10641955.2019.1640725.

54. Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: Clinical clues from complement genetics. Nature Reviews Nephrology. 2021;17 (8):543–553. DOI: https://doi.org/10.1038/s41581-021-00424-4.

55. Zununi Vahed S, Rahbar Saadat Y, Ardalan M. Thrombotic microangiopathy during pregnancy. Microvascular Research. 2021;138:104226. DOI: https://doi.org/10.1016/j.mvr.2021.104226.

56. Burwick RM, Feinberg BB. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics & Gynecology. 2022;226 (2Suppl): S1059–S1070. DOI: https://doi.org/10.1016/j.ajog.2020.09.038.

57. Gäckler A, Witzke O. Thrombotic microangiopathy. Der Nephrologe. 2021;16(2):113–123. (In Germ.). DOI: https://doi.org/10.1007/s11560-021-00487-1.

58. Greenbaum LA. Atypical hemolytic uremic syndrome. Advances in Pediatrics. 2014;61(1):335–356. DOI: https://doi.org/10.1016/j.yapd.2014.04.001.

59. Gupta M, Govindappagari S, Burwick RM. Pregnancy-associated atypical hemolytic uremic syndrome: A systematic review. Obstetrics& Gynecology. 2020;135(1):46–58. DOI: https://doi.org/10.1097/AOG.0000000000003554.

60. Gupta M, Feinberg BB, Burwick RM. Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertension. 2018;12:29–34. DOI: https://doi.org/10.1016/j.preghy.2018.02.007.

61. Korotchaeva YuV, Kozlovskaya NL, Shifman EM, Guryeva VM, Apresyan SV. Atypical hemolytic uremic syndrome and pre-eclampsia: Cause or effect? Gynecology, Obstetrics and Perinatology. 2021;20(4):55–63. (In Russ.). DOI: https://doi.org/10.20953/1726-1678-2021-4-55-63.

62. Kozlovskaya NL, Korotchaeva YuV, Shifman YeM, Kudlay DA. Pregnancy-associated atypical hemolytic-uremic syndrome: Is pregnancy to blame or its complications? Gynecology, Obstetrics and Perinatology. 2020;19(4):81–91. (In Russ.). DOI: https://doi.org/10.20953/1726-1678-2020-4-81-91.

63. Jiang R, Wang T, Li B, He J. Clinical characteristics and pregnancy outcomes of atypical hemolysis, elevated liver enzymes, and low platelets syndrome: A case series. Medicine. 2020;99(18):e19798. DOI: https://doi.org/10.1097/MD.0000000000019798.

64. Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Eloundou S, et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2018;3(6):e99128. DOI: https://doi.org/10.1172/jci.insight.99128.

65. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction. American Journal of Obstetrics & Gynecology. 2022;226(2Suppl):S1071–S1097.e2. DOI: https://doi.org/10.1016/j.ajog.2020.07.020.

66. Balyan K, Humtso BY, Meena B, Sapna S, Rana A, Kumar M. Materno-fetal outcome with PlGF above or below cutoff during second half of pregnancy in high-risk women. International Journal of Gynecology & Obstetrics. 2024;165(1):211–219. DOI: https://doi.org/10.1002/ijgo.15143.

67. Muñoz-Hernández R, Medrano-Campillo P, Miranda ML, Macher HC, Praena-Fernández JM, Vallejo-Vaz AJ, et al. Total and fetal circulating cell-free DNA, angiogenic, and antiangiogenic factors in preeclampsia and HELLP syndrome. American Journal of Hypertension. 2017;30(7):673–682. DOI: https://doi.org/10.1093/ajh/hpx024.

68. Wei L, Liping Z, Suya K. Expression of insulin-like growth factor binding protein-3 in HELLP syndrome. BMC Pregnancy and Childbirth. 2023;23(1):778. DOI: https://doi.org/10.1186/s12884-023-06074-7.